The anti-proliferative effects of type I IFN involve STAT6-mediated regulation of SP1 and BCL6

Cancer Letters

Volumn 375, Issue 2, 2016, Pages 303-312

  Hsu, Yu An ^a   Huang, Chi Chun ^b   Kung, Yung Jen ^c   Lin, Hui Ju ^d,e   Chang, Ching Yao ^f   Lee, Kuan Rong ^a   Wan, Lei ^d,e,f  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

Author keywords

Anti proliferation activities; BCL6; Interferon alpha; Interferon beta; Sp1; STAT6

Indexed keywords

INTERFERON; MESSENGER RNA; PROTEIN BCL 6; SMALL INTERFERING RNA; SP1 PROTEIN; STAT2 PROTEIN; STAT6 PROTEIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; SP1 PROTEIN, HUMAN; STAT2 PROTEIN, HUMAN; STAT6 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SP1;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BCL6 GENE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DAUDI CELL LINE; DOWN REGULATION; DRUG SENSITIVITY; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SP1 GENE; UPREGULATION; B LYMPHOCYTE; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

B-LYMPHOCYTES; CELL PROLIFERATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERFERON-ALPHA; NEOPLASMS; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR;

EID: 84961282473     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.047     Document Type: Article

References (54)

1. Pfeffer L.M., Dinarello C.A., Herberman R.B., Williams B.R., Borden E.C., Bordens R., et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998, 58:2489-2499.
2. Caraglia M., Marra M., Pelaia G., Maselli R., Caputi M., Marsico S.A., et al. Alpha-interferon and its effects on signal transduction pathways. J. Cell. Physiol 2005, 202:323-335.
3. Kotenko S.V., Pestka S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 2000, 19:2557-2565.
4. Leonard W.J. Role of Jak kinases and STATs in cytokine signal transduction. Int. J. Hematol 2001, 73:271-277.
5. Pfeffer L.M., Stebbing N., Donner D.B. Cytoskeletal association of human alpha-interferon-receptor complexes in interferon-sensitive and -resistant lymphoblastoid cells. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:3249-3253.
6. O'Shea J.J. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet?. Immunity 1997, 7:1-11.
7. Schindler C., Shuai K., Prezioso V.R., Darnell J.E. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 1992, 257:809-813.
8. Schindler C., Fu X.-Y., Improta T., Aebersold R., Darnell J.E. Proteins of transcription factor ISGF-3: one gene encodes the 91- and 84-kDa ISGF-3 proteins that are activated by interferon a. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:7836.
9. Wurster A.L., Tanaka T., Grusby M.J. The biology of Stat4 and Stat6. Oncogene 2000, 19:2577-2584.
10. Yang C.H., Shi W., Basu L., Murti A., Constantinescu S.N., Blatt L., et al. Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J. Biol. Chem 1996, 271:8057-8061.
11. Meinke A., Barahmand-Pour F., Wohrl S., Stoiber D., Decker T. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol. Cell. Biol 1996, 16:6937-6944.
12. Cho S.S., Bacon C.M., Sudarshan C., Rees R.C., Finbloom D., Pine R., et al. Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J. Immunol 1996, 157:4781-4789.
13. Bruns H.A., Kaplan M.H. The role of constitutively active Stat6 in leukemia and lymphoma. Crit. Rev. Oncol. Hematol 2006, 57:245-253.
14. Ansel K.M., Djuretic I., Tanasa B., Rao A. Regulation of Th2 differentiation and Il4 locus accessibility. Annu. Rev. Immunol 2006, 24:607-656.
15. Ostrand-Rosenberg S., Grusby M.J., Clements V.K. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol 2000, 165:6015-6019.
16. Ostrand-Rosenberg S., Sinha P., Clements V., Dissanayake S.I., Miller S., Davis C., et al. Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease. Cancer Immunol. Immunother 2004, 53:86-91.
17. Kacha A.K., Fallarino F., Markiewicz M.A., Gajewski T.F. Spontaneous rejection of poorly immunogenic P1.HTR tumors by stat6-deficient mice. J. Immunol 2000, 165:6024-6028.
18. Suske G. The Sp-family of transcription factors. Gene 1999, 238:291-300.
19. Pan D., Courey A.J. The same dorsal binding site mediates both activation and repression in a context-dependent manner. EMBO J. 1992, 11:1837-1842.
20. Bin L., Howell M.D., Kim B.E., Streib J.E., Hall C.F., Leung D.Y. Specificity protein 1 is pivotal in the skin's antiviral response. J. Allergy Clin. Immunol 2011, 127:430-438. e431-432.
21. Albagli-Curiel O. Ambivalent role of BCL6 in cell survival and transformation. Oncogene 2003, 22:507-516.
22. Artiga M.J., Saez A.I., Romero C., Sanchez-Beato M., Mateo M.S., Navas C., et al. A short mutational hot spot in the first intron of BCL-6 is associated with increased BCL-6 expression and with longer overall survival in large B-cell lymphomas. Am. J. Pathol 2002, 160:1371-1380.
23. Hurtz C., Hatzi K., Cerchietti L., Braig M., Park E., Kim Y.M., et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J. Exp. Med 2011, 208:2163-2174.
24. Gallavotti A., Zhao Q., Kyozuka J., Meeley R.B., Ritter M.K., Doebley J.F., et al. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004, 432:630-635.
25. Yildiz M., Li H., Bernard D., Amin N.A., Ouillette P., Jones S., et al. Activating STAT6 mutations in follicular lymphoma. Blood 2015, 125:668-679.
26. Ritz O., Guiter C., Castellano F., Dorsch K., Melzner J., Jais J.P., et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 2009, 114:1236-1242.
27. Hebenstreit D., Wirnsberger G., Horejs-Hoeck J., Duschl A. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev 2006, 17:173-188.
28. Georas S.N., Cumberland J.E., Burke T.F., Chen R., Schindler U., Casolaro V. Stat6 inhibits human interleukin-4 promoter activity in T cells. Blood 1998, 92:4529-4538.
29. Schindler C., Kashleva H., Pernis A., Pine R., Rothman P. STF-IL-4: a novel IL-4-induced signal transducing factor. EMBO J. 1994, 13:1350-1356.
30. Kohler I., Rieber E.P. Allergy-associated I epsilon and Ec epsilon receptor II (CD23b) genes activated via binding of an interleukin-4-induced transcription factor to a novel responsive element. Eur. J. Immunol 1993, 23:3066-3071.
31. Du Z., Fan M., Kim J.G., Eckerle D., Lothstein L., Wei L., et al. Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents. J. Biol. Chem 2009, 284:27808-27815.
32. Lindner D.J., Kalvakolanu D.V., Borden E.C. Increasing effectiveness of interferon-alpha for malignancies. Semin. Oncol 1997, 24:S9-99-S99-104.
33. McLaughlin P. The role of interferon in the therapy of malignant lymphoma. Biomed. Pharmacother 1996, 50:140-148.
34. Willmes C., Adam C., Alb M., Volkert L., Houben R., Becker J.C., et al. Type I and II IFNs inhibit Merkel cell carcinoma via modulation of the Merkel cell polyomavirus T antigens. Cancer Res 2012, 72:2120-2128.
35. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
36. Copeland N.G., Gilbert D.J., Schindler C., Zhong Z., Wen Z., Darnell J.E., et al. Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics 1995, 29:225-228.
37. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
38. Gupta S., Jiang M., Pernis A.B. IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. J. Immunol 1999, 163:3834-3841.
39. Fasler-Kan E., Pansky A., Wiederkehr M., Battegay M., Heim M.H. Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur. J. Biochem 1998, 254:514-519.
40. Wan L., Lin C.W., Lin Y.J., Sheu J.J., Chen B.H., Liao C.C., et al. Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer. J. Cell. Mol. Med 2008, 12:876-888.
41. Elo L.L., Jarvenpaa H., Tuomela S., Raghav S., Ahlfors H., Laurila K., et al. Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming. Immunity 2010, 32:852-862.
42. Ricardo-Gonzalez R.R., Red Eagle A., Odegaard J.I., Jouihan H., Morel C.R., Heredia J.E., et al. IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:22617-22622.
43. Wei M., Liu B., Gu Q., Su L., Yu Y., Zhu Z. Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1). Cell. Oncol. (Dordr.) 2013, 36:79-93.
44. Black A.R., Black J.D., Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J. Cell. Physiol 2001, 188:143-160.
45. Marin M., Karis A., Visser P., Grosveld F., Philipsen S. Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell 1997, 89:619-628.
46. Lou Z., O'Reilly S., Liang H., Maher V.M., Sleight S.D., McCormick J.J. Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005, 65:1007-1017.
47. Deniaud E., Baguet J., Mathieu A.L., Pages G., Marvel J., Leverrier Y. Overexpression of Sp1 transcription factor induces apoptosis. Oncogene 2006, 25:7096-7105.
48. Chuang J.Y., Wu C.H., Lai M.D., Chang W.C., Hung J.J. Overexpression of Sp1 leads to p53-dependent apoptosis in cancer cells. Int. J. Cancer 2009, 125:2066-2076.
49. Albagli O., Lantoine D., Quief S., Quignon F., Englert C., Kerckaert J.P., et al. Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci. Oncogene 1999, 18:5063-5075.
50. Yamochi T., Kaneita Y., Akiyama T., Mori S., Moriyama M. Adenovirus-mediated high expression of BCL-6 in CV-1 cells induces apoptotic cell death accompanied by down-regulation of BCL-2 and BCL-X(L). Oncogene 1999, 18:487-494.
51. Shaffer A.L., Yu X., He Y., Boldrick J., Chan E.P., Staudt L.M. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000, 13:199-212.
52. Mikita T., Daniel C., Wu P., Schindler U. Mutational analysis of the STAT6 SH2 domain. J. Biol. Chem 1998, 273:17634-17642.
53. Schindler U., Wu P., Rothe M., Brasseur M., McKnight S.L. Components of a Stat recognition code: evidence for two layers of molecular selectivity. Immunity 1995, 2:689-697.
54. Leung S., Qureshi S.A., Kerr I.M., Darnell J.E., Stark G.R. Role of STAT2 in the alpha interferon signaling pathway. Mol. Cell. Biol 1995, 15:1312-1317.